Delivering an immune therapy into tumours instead of intravenously reduces adverse effects

In people with advanced skin cancer, injecting low doses of an anticancer immunotherapy directly into tumours, rather than administering high doses intravenously, reduced severe immune toxicity while preserving antitumour efficacy. Pre-existing antitumour immunity predicted clinical benefit most strongly, and profiling fresh tissue provided response biomarkers faster than conventional diagnostics did.